Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.

Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D; 089 Study Group.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):161-7.

PMID:
17971713
2.

[Efficacy of atazanavir in treatment-naive patients].

Moreno S, Hernández B, Dronda F.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:9-13. doi: 10.1016/S0213-005X(08)76614-X. Review. Spanish.

PMID:
20116611
3.

[Clinical utility of atazanavir].

Ribera Pascuet E, Curran A.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:55-67. doi: 10.1016/S0213-005X(08)76622-9. Review. Spanish.

PMID:
20116619
4.

The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.

Chetchotisakd P.

Expert Rev Anti Infect Ther. 2009 Sep;7(7):801-5. doi: 10.1586/eri.09.66. Review.

PMID:
19735222
5.

Atazanavir: a review of its use in the management of HIV infection.

Swainston Harrison T, Scott LJ.

Drugs. 2005;65(16):2309-36. Review.

PMID:
16266202
6.

[Efficacy of atazanavir in simplification regimens].

Zamora L, Gatell JM.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:14-21. doi: 10.1016/S0213-005X(08)76615-1. Review. Spanish.

PMID:
20116612
7.

[Efficacy of atazanavir in rescue therapy].

Portilla J, Boix V, Merino E, Reus S.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:22-7. doi: 10.1016/S0213-005X(08)76616-3. Review. Spanish.

PMID:
20116613
8.

Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review.

Gianotti N, Soria A, Lazzarin A.

New Microbiol. 2007 Apr;30(2):79-88. Review.

9.
10.

Atazanavir: in pediatric patients with HIV-1 infection.

Deeks ED.

Paediatr Drugs. 2012 Apr 1;14(2):131-41. doi: 10.2165/11208550-000000000-00000. Review.

PMID:
22292486
11.
12.

Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.

Cahn PE, Gatell JM, Squires K, Percival LD, Piliero PJ, Sanne IA, Shelton S, Lazzarin A, Odeshoo L, Kelleher TD, Thiry A, Giordano MD, Schnittman SM.

J Int Assoc Physicians AIDS Care (Chic). 2004 Jul-Sep;3(3):92-8. Review.

PMID:
15573713
13.

Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials.

Carey D, Amin J, Boyd M, Petoumenos K, Emery S.

J Antimicrob Chemother. 2010 Sep;65(9):1878-88. doi: 10.1093/jac/dkq231. Epub 2010 Jun 16. Review.

PMID:
20554568
14.

Atazanavir: simplicity and convenience in different scenarios.

Pérez-Elías MJ.

Expert Opin Pharmacother. 2007 Apr;8(5):689-700. Review.

PMID:
17376023
15.

Atazanavir for the treatment of human immunodeficiency virus infection.

Busti AJ, Hall RG, Margolis DM.

Pharmacotherapy. 2004 Dec;24(12):1732-47. Review.

PMID:
15585441
16.

Clinical pharmacology, efficacy and safety of atazanavir: a review.

Bentué-Ferrer D, Arvieux C, Tribut O, Ruffault A, Bellissant E.

Expert Opin Drug Metab Toxicol. 2009 Nov;5(11):1455-68. doi: 10.1517/17425250903321514. Review.

PMID:
19863454
17.

Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection.

Kaplan SS, Hicks CB.

J Antimicrob Chemother. 2005 Aug;56(2):273-6. Epub 2005 Jun 30. Review.

PMID:
15994247
18.

Atazanavir: new option for treatment of HIV infection.

Havlir DV, O'Marro SD.

Clin Infect Dis. 2004 Jun 1;38(11):1599-604. Epub 2004 May 13. Review.

PMID:
15156449
19.
20.

Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy.

Cahn P.

Expert Opin Investig Drugs. 2004 Jan;13(1):55-68. Review.

PMID:
14680453

Supplemental Content

Support Center